29
Dec
On Tuesday Sun Pharma said, its subsidiary has received authorization for emergency use from the Drugs Controller General of India to manufacture and market a generic version of MSD and Ridgeback's antiviral drug molnupiravir under the brand name Molxvir in India. The recommended dose of the drug is 800 mg twice a day for five days.The duration of treatment of molnupiravir is much shorter compared to other therapies which is a significant advantage. Molnupiravir has been developed by MSD and Ridgeback Biotherapeutics.It has been approved by the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory…